Takeda Pharmaceutical Co (0RN3) Stock Statistics & Valuation Metrics

Takeda Pharmaceutical Co has a market cap or net worth of EUR 60.12B. The enterprise value is EUR 13.51T.

Market Cap

EUR 60.12B

Enterprise Value

EUR 13.51T

Takeda Pharmaceutical Co has 1,602,218,500 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

1,602,218,500

Owned by Insiders

0.19%

Owned by Institutions

25.00%

Takeda Pharmaceutical Co’s return on equity (ROE) is 0.02 and return on invested capital (ROIC) is 2.95%.

Return on Equity (ROE)

0.02

Return on Assets (ROA)

0.01

Return on Invested Capital (ROIC)

2.95%

Return on Capital Employed (ROCE)

0.04

Revenue Per Employee

95.81M

Profits Per Employee

4.08M

Employee Count

47,029

Asset Turnover

0.29

Inventory Turnover

1.58

The current PE Ratio of Takeda Pharmaceutical Co is 27.15. Takeda Pharmaceutical Co’s PEG ratio is 0.03.

PE Ratio

27.15

PS Ratio

2.26

PB Ratio

1.40

Price to FCF

18.06

Price to Operating Cash Flow

13.41

PEG Ratio

0.03

In the last 12 months, Takeda Pharmaceutical Co had revenue of 4.51T and earned 191.76B in profits. Earnings per share was 121.75.

Revenue

4.51T

Gross Profit

2.30T

Operating Income

540.45B

Pretax Income

260.19B

Net Income

191.76B

EBITDA

1.34T

Earnings Per Share (EPS)

121.75

In the last 12 months, operating cash flow was 774.55B and capital expenditures -186.50B, giving a free cash flow of 588.05B billion.

Operating Cash Flow

774.55B

Free Cash Flow

588.05B

Free Cash Flow per Share

376.34

Takeda Pharmaceutical Co pays an annual dividend of ―, resulting in a dividend yield of 3.45%

Dividend Per Share

―

Dividend Yield

3.45%

Payout Ratio

N/A

Free Cash Flow Yield

5.54%

Earnings Yield

3.71%

Beta

―

52-Week Price Change

0.00%

50-Day Moving Average

35.20

200-Day Moving Average

35.20

Relative Strength Index (RSI)

―

Average Volume (3m)

―

Takeda Pharmaceutical Co upcoming earnings date is Jan 28, 2027, TBA (Not Confirmed).

Last Earnings Date

Oct 29, 2026

Next Earnings Date

Jan 28, 2027

Ex-Dividend Date

―

Takeda Pharmaceutical Co as a current ratio of 1.27, with Debt / Equity ratio of 62.80%

Current Ratio

1.27

Quick Ratio

0.70

Debt to Market Cap

0.55

Net Debt to EBITDA

3.20

Interest Coverage Ratio

1.51

In the past 12 months, Takeda Pharmaceutical Co has paid 68.16B in taxes.

Income Tax

68.16B

Effective Tax Rate

0.26

Takeda Pharmaceutical Co EV to EBITDA ratio is 11.20, with an EV/FCF ratio of 25.13.

EV to Sales

3.15

EV to EBITDA

11.20

EV to Free Cash Flow

25.13

EV to Operating Cash Flow

19.08

Takeda Pharmaceutical Co has EUR 454.40B in cash and marketable securities with EUR 4.58T in debt, giving a net cash position of -EUR 4.12T billion.

Cash & Marketable Securities

EUR 454.40B

Total Debt

EUR 4.58T

Net Cash

-EUR 4.12T

Net Cash Per Share

-EUR 2,572.21

Tangible Book Value Per Share

-EUR 950.59

Gross margin is 62.49%, with operating margin of 13.26%, and net profit margin of 8.20%.

Gross Margin

62.49%

Operating Margin

13.26%

Pretax Margin

8.52%

Net Profit Margin

8.20%

EBITDA Margin

28.12%

EBIT Margin

14.80%

The average price target for Takeda Pharmaceutical Co is EUR 39.45, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

EUR 39.45

Price Target Upside

12.08% Upside

Analyst Consensus

Strong Buy

Analyst Count

4

Revenue Growth Forecast

-4.28%

EPS Growth Forecast

12.37%